Skip to Content

Tag: ASP


Also Noted

OIG: Part B drugs exceed AMP threshold 

February 18, 2021HME News Staff

WASHINGTON – Seven codes for Medicare Part B drugs met CMS’s price substitution criteria by exceeding the 5% threshold for wo consecutive quarters or three of the four previous quarters, according to a new report from the Office of Inspector General. To conduct the study, the OIG calculated the volume-weighted average manufacturer’s price for each drug, consistent with CMS's methodology for calculating volume-weighted average sales prices. The OIG is providing...

ASP, Average Sales Price, Part B drugs


Read Full Articlered right arrow icon

Also Noted

OIG: ASP continues to exceed AMP for certain drugs

March 10, 2020HME News Staff

WASHINGTON - The average sales price for 11 drug codes in the third quarter of 2019 met CMS's price substitution criteria by exceeding the average manufacturer price by 5% for two consecutive quarters or three of the previous four quarters, according to a new report from the Office of Inspector General. When the ASP exceeds the AMP by 5%, the Department of Health and Human Services substitutes the ASP-based amount with a lower calculated rate, either 103% of the AMP or the widely available market...

AMP, ASP, OIG, Part B drugs, Pricing


Read Full Articlered right arrow icon

Also Noted

OIG recommends CMS review Part B drug prices

May 16, 2019HME News Staff

WASHINGTON - The average sales price for 10 drug codes for the fourth quarter of 2018 exceeded the average manufacture price by 5% or more for two consecutive quarters, according to a new report from the Office of Inspector General. Another five drug codes exceeded the AMP by at least 5% during the quarter but did not meet other price substitution criteria. When the ASP exceeds the AMP by 5%, the Department of Health and Human Services substitutes the ASP-based amount with a lower calculated rate,...

ASP, Average Sales Price, Part B drugs


Read Full Articlered right arrow icon

Also Noted

NHIA responds to OIG report on infusion payments

September 16, 2016HME News Staff

ALEXANDRIA, Va. - A recent Office of Inspector General report on payment for Part B DME infusion drugs is far too narrow to be the basis for new policy, according to the National Home Infusion Association. The OIG's report recommends that CMS seek a legislative change that would require payments for DME infusion drugs to be based on average sales prices (ASPs), average wholesales prices from 2003. The NHIA argues, however, that Congress should “fix” the payment issue by passing the...

ASP, AWP, Home Infusion, OIG, Reimbursement


Read Full Articlered right arrow icon

Also Noted

Senators want to review home infusion pricing with CMS

September 24, 2015HME News Staff

Senators want to review home infusion pricing with CMS WASHINGTON - More than a dozen senators have written a letter to Senate Majority Leader Mitch McConnell and Minority Leader Harry Reid asking for time to review S. 275, the Medicare Home Infusion Site of Care Act, with CMS. “We urge that the average sales price pricing provisions from H.R. 6 or H.R. 2570 not be included in any legislation that does not recognize the services component of care that is included in S. 275,” stated the...

ASP, Home Infusion, Medicare Home Infusion Site of Care Act


Read Full Articlered right arrow icon

Also Noted

ASP rises for several drugs

September 23, 2015HME News Staff

BALTIMORE - Fourth-quarter payments showed healthy increases for several respiratory drugs. Brand name drugs Brovana (J7605) rose 88 cents to $8.08 per dose and Perforomist (J7606) rose 40 cents to $8.88 per dose. Budesonide (J7626) was up 19 cents to $5.39 per dose. Ipratropium (J7644) was unchanged at just under 11 cents per dose. Albuterol (J7613) was down nearly 2 cents to just under 12 cents per dose.

ASP, Neb-med prices, respiratory meds


Also Noted

OIG: CMS overpays for infusion drugs

April 23, 2015HME News Staff

WASHINGTON - CMS could have saved $251 million over an 18-month period if it paid for DME infusion drugs using an average sales price methodology, according to a new report from the Office of Inspector General. While most Part B drugs are paid at 106% of the ASP, infusion drugs are paid at 95% of the average wholesale price. Between the second quarter of 2013 and the third quarter of 2014, at least 42% of infusion drugs were paid at amounts that were more than twice their estimated acquisition costs,...

ASP, Infusion drugs


Read Full Articlered right arrow icon

Specialty Providers

ASP: Budesonide back down

April 26, 2013Theresa Flaherty, Managing Editor

BALTIMORE - Pricing for budesonide took a plunge in the latest average sales price (ASP) figures for respiratory medications released in March.Budesonide (J7626) decreased 49 cents to $4.76 per dose for second quarter 2013. In the previous quarter, the drug saw an increase of 38 cents, to $5.26 per dose. Although a third generic version of budesonide has recently hit the market, it has had very limited distribution in the DME space and shouldn't have had much of an impact on pricing, says Wayne Vega,...

Albuterol, ASP, Neb meds


Read Full Articlered right arrow icon

News

In brief: ResMed lawsuit, surety bond update

March 29, 2013HME News Staff

SAN DIEGO - ResMed has sued Taiwanese manufacturer Apex Medical and its U.S. distributor, Medical Depot, doing business as Drive Medical, to stop alleged patent infringement. ResMed has filed parallel legal actions in the International Trade Commission (ITC) and U.S. federal court, alleging its patents are being infringed by several Apex products, including the Wizard 210 and 220 masks; the Freedom 210 and 220 masks made by Apex and sold by Medical Depot; and the iCH and XT Fit flow generators. “We...

ASP, Drive Medical, ResMed, surety bonds


Read Full Articlered right arrow icon